NEUREN PHARMACEUTICALS LIMITED - Announcements

5.76%

$13.10

Market Cap $1.629B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Announcements

Filter Results

All Price Sensitive Only

NEU	Appendix 3B-NEU.AX		28/10/16	104.16KB	Share
NEU	Change of Director's Interest Notice-NEU.AX		31/08/16	77.11KB	Share
NEU	Appendix 3B-NEU.AX		31/08/16	104.22KB	Share
NEU	Half Yearly Report and Accounts-NEU.AX	PRICE SENSITIVE	30/08/16	459.62KB	Share
NEU	Neuren expands Phase 2 Rett syndrome pediatric trial-NEU.AX	PRICE SENSITIVE	28/08/16	121.69KB	Share
NEU	Neuren expands Phase 2 Rett syndrome pediatric trial-NEU.AX	PRICE SENSITIVE	25/08/16	121.69KB	Share
NEU	Appendix 4C - quarterly-NEU.AX	PRICE SENSITIVE	26/07/16	55.42KB	Share
NEU	Neuren presents at Rettsyndrome.org 2016 Research Symposium-NEU.AX	PRICE SENSITIVE	24/06/16		Share
NEU	Neuren presents at Rettsyndrome.org 2016 Research Symposium-NEU.AX	PRICE SENSITIVE	24/06/16	1.93MB	Share
NEU	Grant of new patent for Autism Spectrum Disorders-NEU.AX	PRICE SENSITIVE	22/06/16	103.21KB	Share
NEU	Results of Meeting-NEU.AX		31/05/16	59.1KB	Share
NEU	Chairman's Address to Shareholders-NEU.AX		31/05/16	117.16KB	Share
NEU	Change of Director's Interest Notice-NEU.AX		16/05/16	76.87KB	Share
NEU	Presentation at 6th Annual TBI Conference, Washington DC-NEU.AX		13/05/16	479.91KB	Share
NEU	Notice of Annual General Meeting/Proxy Form-NEU.AX		02/05/16	457.14KB	Share
NEU	Appendix 4C - quarterly-NEU.AX	PRICE SENSITIVE	29/04/16	55.33KB	Share
NEU	Neuren Shareholder Update-NEU.AX		26/04/16	106.6KB	Share
NEU	Results of Phase 2 trial in moderate to severe TBI-NEU.AX	PRICE SENSITIVE	26/04/16	114.81KB	Share
NEU	Trading Halt-NEU.AX	PRICE SENSITIVE	22/04/16	315.99KB	Share
NEU	Appendix 4G-NEU.AX		18/04/16	122.29KB	Share
NEU	Annual Report to shareholders-NEU.AX		18/04/16	1.48MB	Share
NEU	First subject commences Neuren's Rett syndrome Phase 2 trial-NEU.AX	PRICE SENSITIVE	07/04/16	104.52KB	Share
NEU	Neuren reports 2015 full-year financial results		25/02/16	141.83KB	Share
NEU	Appendix 4E and Financial Report 31 December 2015	PRICE SENSITIVE	25/02/16	628.22KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/16	55.25KB	Share
NEU	Neuren Investor Presentation, 11 January 2016		11/01/16	433.19KB	Share
NEU	Neuren Shareholder Update, January 2016		04/01/16	112.74KB	Share
NEU	Appendix 3B		30/12/15	105.8KB	Share
NEU	Trofinetide successful in Phase 2 trial in Fragile X	PRICE SENSITIVE	07/12/15	266.53KB	Share
NEU	Trading Halt	PRICE SENSITIVE	03/12/15	144.62KB	Share
NEU	Grant of composition patent in Europe for Neuren's NNZ-2591	PRICE SENSITIVE	30/11/15	99.37KB	Share
NEU	Corporations Act Notice		17/11/15	27.18KB	Share
NEU	Appendix 3B		17/11/15	106.02KB	Share
NEU	Shareholders provide further support for Rett syndrome	PRICE SENSITIVE	09/11/15	103.44KB	Share
NEU	Neuren completes enrolment in INTREPID clinical trial	PRICE SENSITIVE	29/10/15	98.93KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/15	55.15KB	Share
NEU	IRSF confirms financial support for Neuren's clinical trials	PRICE SENSITIVE	13/10/15	105.91KB	Share
NEU	New US patent covering use of trofinetide for Rett syndrome	PRICE SENSITIVE	12/10/15	102.34KB	Share
NEU	Neuren provides update on Fragile X and INTREPID trials		29/09/15	100.57KB	Share
NEU	Half Yearly Report and Accounts 30 June 2015	PRICE SENSITIVE	25/08/15	2.33MB	Share
NEU	trofinetide confirmed as INN for Neuren's NNZ-2566		14/08/15	103.33KB	Share
NEU	Neuren confirms orphan drug designations in Europe	PRICE SENSITIVE	13/08/15	102.28KB	Share
NEU	Investor presentation, 31 July 2015		31/07/15	366.21KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/15	54.99KB	Share
NEU	Neuren reports progress in orphan drug programs	PRICE SENSITIVE	29/07/15	119.75KB	Share
NEU	Appendix 3B		01/06/15	105.81KB	Share
NEU	Appendix 3B		07/05/15	99.95KB	Share
NEU	Results of Meeting		28/04/15	58.09KB	Share
NEU	Chairman's Address to Shareholders		28/04/15	123.46KB	Share
NEU	Appendix 3B		22/04/15	105.77KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	21/04/15	54.92KB	Share
NEU	Appendix 3B		26/03/15	105.86KB	Share
NEU	Notice of Annual General Meeting/Proxy Form		25/03/15	420.36KB	Share
NEU	Annual Report to shareholders		25/03/15	1.74MB	Share
NEU	Neuren receives response to request for Breakthrough Therapy	PRICE SENSITIVE	02/03/15	106.95KB	Share
NEU	Neuren reports 2014 full-year financial results		25/02/15	142.13KB	Share
NEU	Preliminary Final Report and 2014 full year accounts	PRICE SENSITIVE	25/02/15	308.57KB	Share
NEU	FDA grants Neuren Orphan Drug designation for Rett syndrome	PRICE SENSITIVE	16/02/15	105.53KB	Share
NEU	Appendix 3B		06/02/15	106.12KB	Share
NEU	Change of Director's Interest Notice		05/02/15	62.03KB	Share
NEU	Updated Share Trading Policy		29/01/15	60.82KB	Share
NEU	Neuren announces trofinetide as proposed INN for NNZ-2566		28/01/15	102.22KB	Share
NEU	Appendix 3B		27/01/15	106.11KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	22/01/15	55.3KB	Share
NEU	Investor Presentation, 8 January 2015		08/01/15	380.28KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	05/01/15	75.62KB	Share
NEU	Neuren submits Orphan Drug/Breakthrough Therapy applications	PRICE SENSITIVE	30/12/14	112.41KB	Share
NEU	Appendix 3B		23/12/14	106.39KB	Share
NEU	Appendix 3B		03/12/14	106.38KB	Share
NEU	Investor presentation, 27 November 2014		27/11/14	316.98KB	Share
NEU	Appendix 3B		20/11/14	106.41KB	Share
NEU	Neuren successful in Rett syndrome Phase 2 trial	PRICE SENSITIVE	12/11/14	307.45KB	Share
NEU	Trading Halt	PRICE SENSITIVE	10/11/14	88.5KB	Share
NEU	Appendix 3B		28/10/14	106.57KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	17/10/14	55.24KB	Share
NEU	Change of Director's Interest Notice		09/10/14	35.37KB	Share
NEU	Appendix 3B		09/10/14	106.38KB	Share
NEU	Appendix 3B		24/09/14	155.18KB	Share
NEU	Issue of long term incentives		24/09/14	63.99KB	Share
NEU	Neuren to release Rett Syndrome trial results in November		24/09/14	102.3KB	Share
NEU	Enrolment commences in Neuren's Concussion Phase 2 trial	PRICE SENSITIVE	08/09/14	104.78KB	Share
NEU	Investor presentation, 4 September 2014		04/09/14	292.6KB	Share
NEU	Appendix 3B		29/08/14	154.18KB	Share
NEU	Neuren reports 2014 half-year financial results		28/08/14	124.36KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/08/14	504.07KB	Share
NEU	Appendix 3B		15/08/14	155KB	Share
NEU	Neuren advances NNZ-2591 towards IND application	PRICE SENSITIVE	12/08/14	105.14KB	Share
NEU	Appendix 3B		22/07/14	154.54KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	18/07/14	55.26KB	Share
NEU	US$3m increase to US Army grant and INTREPID outlook update	PRICE SENSITIVE	17/07/14	103.73KB	Share
NEU	Neuren receives ethics approval to start Concussion trial	PRICE SENSITIVE	10/07/14	103.23KB	Share
NEU	Neuren completes enrolment in Phase 2 trial in Rett Syndrome	PRICE SENSITIVE	26/06/14	99.27KB	Share
NEU	Appendix 3B		25/06/14	154.27KB	Share
NEU	Neuren appoints CMC expert to leadership team		23/06/14	107.99KB	Share
NEU	Neuren receives new US patent for NNZ-2591	PRICE SENSITIVE	04/06/14	94.34KB	Share
NEU	Appendix 3B		03/06/14	157.88KB	Share
NEU	Appendix 3B		03/06/14	157.89KB	Share
NEU	Appendix 3B		30/05/14	154.2KB	Share
NEU	Neuren presents at International Meeting for Autism Research		21/05/14	2.73MB	Share
NEU	Appendix 3B		14/05/14	154.21KB	Share

NEU Appendix 3B-NEU.AX
28/10/16		104.16KB	Share
NEU Change of Director's Interest Notice-NEU.AX
31/08/16		77.11KB	Share
NEU Appendix 3B-NEU.AX
31/08/16		104.22KB	Share
NEU Half Yearly Report and Accounts-NEU.AX
30/08/16	PRICE SENSITIVE	459.62KB	Share
NEU Neuren expands Phase 2 Rett syndrome pediatric trial-NEU.AX
28/08/16	PRICE SENSITIVE	121.69KB	Share
NEU Neuren expands Phase 2 Rett syndrome pediatric trial-NEU.AX
25/08/16	PRICE SENSITIVE	121.69KB	Share
NEU Appendix 4C - quarterly-NEU.AX
26/07/16	PRICE SENSITIVE	55.42KB	Share
NEU Neuren presents at Rettsyndrome.org 2016 Research Symposium-NEU.AX
24/06/16	PRICE SENSITIVE		Share
NEU Neuren presents at Rettsyndrome.org 2016 Research Symposium-NEU.AX
24/06/16	PRICE SENSITIVE	1.93MB	Share
NEU Grant of new patent for Autism Spectrum Disorders-NEU.AX
22/06/16	PRICE SENSITIVE	103.21KB	Share
NEU Results of Meeting-NEU.AX
31/05/16		59.1KB	Share
NEU Chairman's Address to Shareholders-NEU.AX
31/05/16		117.16KB	Share
NEU Change of Director's Interest Notice-NEU.AX
16/05/16		76.87KB	Share
NEU Presentation at 6th Annual TBI Conference, Washington DC-NEU.AX
13/05/16		479.91KB	Share
NEU Notice of Annual General Meeting/Proxy Form-NEU.AX
02/05/16		457.14KB	Share
NEU Appendix 4C - quarterly-NEU.AX
29/04/16	PRICE SENSITIVE	55.33KB	Share
NEU Neuren Shareholder Update-NEU.AX
26/04/16		106.6KB	Share
NEU Results of Phase 2 trial in moderate to severe TBI-NEU.AX
26/04/16	PRICE SENSITIVE	114.81KB	Share
NEU Trading Halt-NEU.AX
22/04/16	PRICE SENSITIVE	315.99KB	Share
NEU Appendix 4G-NEU.AX
18/04/16		122.29KB	Share
NEU Annual Report to shareholders-NEU.AX
18/04/16		1.48MB	Share
NEU First subject commences Neuren's Rett syndrome Phase 2 trial-NEU.AX
07/04/16	PRICE SENSITIVE	104.52KB	Share
NEU Neuren reports 2015 full-year financial results
25/02/16		141.83KB	Share
NEU Appendix 4E and Financial Report 31 December 2015
25/02/16	PRICE SENSITIVE	628.22KB	Share
NEU Appendix 4C - quarterly
29/01/16	PRICE SENSITIVE	55.25KB	Share
NEU Neuren Investor Presentation, 11 January 2016
11/01/16		433.19KB	Share
NEU Neuren Shareholder Update, January 2016
04/01/16		112.74KB	Share
NEU Appendix 3B
30/12/15		105.8KB	Share
NEU Trofinetide successful in Phase 2 trial in Fragile X
07/12/15	PRICE SENSITIVE	266.53KB	Share
NEU Trading Halt
03/12/15	PRICE SENSITIVE	144.62KB	Share
NEU Grant of composition patent in Europe for Neuren's NNZ-2591
30/11/15	PRICE SENSITIVE	99.37KB	Share
NEU Corporations Act Notice
17/11/15		27.18KB	Share
NEU Appendix 3B
17/11/15		106.02KB	Share
NEU Shareholders provide further support for Rett syndrome
09/11/15	PRICE SENSITIVE	103.44KB	Share
NEU Neuren completes enrolment in INTREPID clinical trial
29/10/15	PRICE SENSITIVE	98.93KB	Share
NEU Appendix 4C - quarterly
21/10/15	PRICE SENSITIVE	55.15KB	Share
NEU IRSF confirms financial support for Neuren's clinical trials
13/10/15	PRICE SENSITIVE	105.91KB	Share
NEU New US patent covering use of trofinetide for Rett syndrome
12/10/15	PRICE SENSITIVE	102.34KB	Share
NEU Neuren provides update on Fragile X and INTREPID trials
29/09/15		100.57KB	Share
NEU Half Yearly Report and Accounts 30 June 2015
25/08/15	PRICE SENSITIVE	2.33MB	Share
NEU trofinetide confirmed as INN for Neuren's NNZ-2566
14/08/15		103.33KB	Share
NEU Neuren confirms orphan drug designations in Europe
13/08/15	PRICE SENSITIVE	102.28KB	Share
NEU Investor presentation, 31 July 2015
31/07/15		366.21KB	Share
NEU Appendix 4C - quarterly
30/07/15	PRICE SENSITIVE	54.99KB	Share
NEU Neuren reports progress in orphan drug programs
29/07/15	PRICE SENSITIVE	119.75KB	Share
NEU Appendix 3B
01/06/15		105.81KB	Share
NEU Appendix 3B
07/05/15		99.95KB	Share
NEU Results of Meeting
28/04/15		58.09KB	Share
NEU Chairman's Address to Shareholders
28/04/15		123.46KB	Share
NEU Appendix 3B
22/04/15		105.77KB	Share
NEU Appendix 4C - quarterly
21/04/15	PRICE SENSITIVE	54.92KB	Share
NEU Appendix 3B
26/03/15		105.86KB	Share
NEU Notice of Annual General Meeting/Proxy Form
25/03/15		420.36KB	Share
NEU Annual Report to shareholders
25/03/15		1.74MB	Share
NEU Neuren receives response to request for Breakthrough Therapy
02/03/15	PRICE SENSITIVE	106.95KB	Share
NEU Neuren reports 2014 full-year financial results
25/02/15		142.13KB	Share
NEU Preliminary Final Report and 2014 full year accounts
25/02/15	PRICE SENSITIVE	308.57KB	Share
NEU FDA grants Neuren Orphan Drug designation for Rett syndrome
16/02/15	PRICE SENSITIVE	105.53KB	Share
NEU Appendix 3B
06/02/15		106.12KB	Share
NEU Change of Director's Interest Notice
05/02/15		62.03KB	Share
NEU Updated Share Trading Policy
29/01/15		60.82KB	Share
NEU Neuren announces trofinetide as proposed INN for NNZ-2566
28/01/15		102.22KB	Share
NEU Appendix 3B
27/01/15		106.11KB	Share
NEU Appendix 4C - quarterly
22/01/15	PRICE SENSITIVE	55.3KB	Share
NEU Investor Presentation, 8 January 2015
08/01/15		380.28KB	Share
NEU Response to ASX Price Query
05/01/15	PRICE SENSITIVE	75.62KB	Share
NEU Neuren submits Orphan Drug/Breakthrough Therapy applications
30/12/14	PRICE SENSITIVE	112.41KB	Share
NEU Appendix 3B
23/12/14		106.39KB	Share
NEU Appendix 3B
03/12/14		106.38KB	Share
NEU Investor presentation, 27 November 2014
27/11/14		316.98KB	Share
NEU Appendix 3B
20/11/14		106.41KB	Share
NEU Neuren successful in Rett syndrome Phase 2 trial
12/11/14	PRICE SENSITIVE	307.45KB	Share
NEU Trading Halt
10/11/14	PRICE SENSITIVE	88.5KB	Share
NEU Appendix 3B
28/10/14		106.57KB	Share
NEU Appendix 4C - quarterly
17/10/14	PRICE SENSITIVE	55.24KB	Share
NEU Change of Director's Interest Notice
09/10/14		35.37KB	Share
NEU Appendix 3B
09/10/14		106.38KB	Share
NEU Appendix 3B
24/09/14		155.18KB	Share
NEU Issue of long term incentives
24/09/14		63.99KB	Share
NEU Neuren to release Rett Syndrome trial results in November
24/09/14		102.3KB	Share
NEU Enrolment commences in Neuren's Concussion Phase 2 trial
08/09/14	PRICE SENSITIVE	104.78KB	Share
NEU Investor presentation, 4 September 2014
04/09/14		292.6KB	Share
NEU Appendix 3B
29/08/14		154.18KB	Share
NEU Neuren reports 2014 half-year financial results
28/08/14		124.36KB	Share
NEU Half Yearly Report and Accounts
28/08/14	PRICE SENSITIVE	504.07KB	Share
NEU Appendix 3B
15/08/14		155KB	Share
NEU Neuren advances NNZ-2591 towards IND application
12/08/14	PRICE SENSITIVE	105.14KB	Share
NEU Appendix 3B
22/07/14		154.54KB	Share
NEU Appendix 4C - quarterly
18/07/14	PRICE SENSITIVE	55.26KB	Share
NEU US$3m increase to US Army grant and INTREPID outlook update
17/07/14	PRICE SENSITIVE	103.73KB	Share
NEU Neuren receives ethics approval to start Concussion trial
10/07/14	PRICE SENSITIVE	103.23KB	Share
NEU Neuren completes enrolment in Phase 2 trial in Rett Syndrome
26/06/14	PRICE SENSITIVE	99.27KB	Share
NEU Appendix 3B
25/06/14		154.27KB	Share
NEU Neuren appoints CMC expert to leadership team
23/06/14		107.99KB	Share
NEUNeuren receives new US patent for NNZ-2591
04/06/14	PRICE SENSITIVE	94.34KB	Share
NEUAppendix 3B
03/06/14		157.88KB	Share
NEUAppendix 3B
03/06/14		157.89KB	Share
NEUAppendix 3B
30/05/14		154.2KB	Share
NEUNeuren presents at International Meeting for Autism Research
21/05/14		2.73MB	Share
NEUAppendix 3B
14/05/14		154.21KB	Share

REFRESH

First 4 5 6 7 8

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.10		Change -0.800(5.76%)		Mkt cap ! $1.629B

Open	High	Low	Value	Volume
$13.95	$13.96	$12.88	$9.534M	725.6K

Buyers (Bids)

No.	Vol.	Price($)
1	266	$13.10

Sellers (Offers)

Price($)	Vol.	No.
$13.15	1619	2

View Market Depth

No.	Vol.	Price($)
1	667	13.080
2	154	13.000
1	77	12.930
1	39	12.920
1	21	12.900

Price($)	Vol.	No.
13.190	1305	1
13.560	2250	1
13.880	748	1
14.000	60	1
14.020	10000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories